BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 36117126)

  • 21. Optimize Local Therapy for Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer to Enhance Survival.
    Chang JY; Verma V
    J Natl Compr Canc Netw; 2022 May; 20(5):531-539. PubMed ID: 35545175
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Stereotaxic ablative radiotherapy in stage 1 non-small-cell lung cancer: Results of the phase 3 randomized trial "CHISEL"].
    Gerard M; Lerouge D; Le Guevelou J; Thariat J
    Bull Cancer; 2020 Feb; 107(2):145-147. PubMed ID: 32035650
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical Outcome of Stereotactic Ablative Body Radiotherapy for Lung Metastatic Lesions in Non-small Cell Lung Cancer Oligometastatic Patients.
    De Rose F; Cozzi L; Navarria P; Ascolese AM; Clerici E; Infante M; Alloisio M; Testori A; Toschi L; Finocchiaro G; Santoro A; Scorsetti M
    Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):13-20. PubMed ID: 26385822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Extracranial stereotactic radiotherapy for early-stage non-small cell lung cancer and oligometastases].
    Riesterer O
    Praxis (Bern 1994); 2013 Oct; 102(21):1309-16. PubMed ID: 24129299
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Radiotherapy for oligometastatic non-small cell lung cancer patients].
    Levy A; Roux C; Mercier O; Issard J; Botticella A; Barlesi F; Le Péchoux C
    Cancer Radiother; 2021 Oct; 25(6-7):517-522. PubMed ID: 34175225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The evolving role of radiotherapy in treatment of oligometastatic NSCLC.
    Bergsma DP; Salama JK; Singh DP; Chmura SJ; Milano MT
    Expert Rev Anticancer Ther; 2015; 15(12):1459-71. PubMed ID: 26536370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stereotactic ablative radiotherapy after concomitant chemoradiotherapy in non-small cell lung cancer: A TITE-CRM phase 1 trial.
    Doyen J; Poudenx M; Gal J; Otto J; Guerder C; Naghavi AO; Gérard A; Leysalle A; Cohen C; Padovani B; Ianessi A; Schiappa R; Chamorey E; Bondiau PY
    Radiother Oncol; 2018 May; 127(2):239-245. PubMed ID: 29650404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stereotactic body radiotherapy improves the survival of patients with oligometastatic non-small cell lung cancer.
    Ouyang W; Yu J; Nuerjiang S; Li Z; Wang D; Wang X; Zhang J; Xie C
    Cancer Med; 2019 Aug; 8(10):4605-4614. PubMed ID: 31245933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Stereotactic radiotherapy of stage I non-small cell lung cancer. State of the art in 2019 and recommendations: Stereotaxy as an alternative to surgery?].
    Kaiss H; Mornex F
    Cancer Radiother; 2019 Oct; 23(6-7):720-731. PubMed ID: 31471255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: Delaying the need to start or change systemic therapy?
    Merino Lara T; Helou J; Poon I; Sahgal A; Chung HT; Chu W; Soliman H; Ung Y; Verma S; Cheema P; Cheng S; Khanna S; Erler D; Zhang L; Cheung P
    Lung Cancer; 2018 Oct; 124():219-226. PubMed ID: 30268464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiation therapy for oligometastatic non-small cell lung cancer.
    Salama JK; Schild SE
    Cancer Metastasis Rev; 2015 Jun; 34(2):183-93. PubMed ID: 25948377
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stereotactic body radiation therapy (stereotactic ablative radiotherapy) for stage I non-small cell lung cancer--updates of radiobiology, techniques, and clinical outcomes.
    Hadziahmetovic M; Loo BW; Timmerman RD; Mayr NA; Wang JZ; Huang Z; Grecula JC; Lo SS
    Discov Med; 2010 May; 9(48):411-7. PubMed ID: 20515609
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oligometastatic breast cancer: where are we now and where are we headed?-a narrative review.
    Kent CL; McDuff SGR; Salama JK
    Ann Palliat Med; 2021 May; 10(5):5954-5968. PubMed ID: 32921069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with "curative" intent.
    Buglione M; Jereczek-Fossa BA; Bonù ML; Franceschini D; Fodor A; Zanetti IB; Gerardi MA; Borghetti P; Tomasini D; Di Muzio NG; Oneta O; Scorsetti M; Franzese C; Romanelli P; Catalano G; Dell'Oca I; Beltramo G; Ivaldi GB; Laudati A; Magrini SM; Antognoni P;
    Lung Cancer; 2020 Mar; 141():1-8. PubMed ID: 31926440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Technical challenges of linac-based stereotactic ablative body radiotherapy: short review for non-radiation oncologists.
    Mihai AM; Rock L; Milano MT
    Ann Palliat Med; 2021 May; 10(5):5931-5943. PubMed ID: 33040563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Setting up a lung stereotactic body radiotherapy service in a tertiary center in Eastern India: The process, quality assurance, and early experience.
    Shrimali RK; Saha A; Arun B; Prasath S; Nallathambi C; Bhoumik S; Mallick I; Achari RB; Chatterjee S
    J Cancer Res Ther; 2020; 16(4):888-899. PubMed ID: 32930136
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Local Ablative Therapies for Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer.
    Jairam V; Park HS; Decker RH
    Cancer J; 2020; 26(2):129-136. PubMed ID: 32205537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Collaborative implementation of stereotactic ablative body radiotherapy: A model for the safe implementation of complex radiotherapy techniques in Australia.
    Hau E; Hegi-Johnson F; Atkinson C; Barber J; Browne LH; Chin Y; Dwyer P; Graham PH; O'Hare J; Lu D; Rains M; Ragusa C; Schmidth L; Small K; Unicomb K; West K; White S; Last A; Ludbrook J; Azzi M; Aherne NJ; Van Tilburg K; Vinod S; Ma X; Yeghiaian Alvandi R
    Asia Pac J Clin Oncol; 2020 Feb; 16(1):39-44. PubMed ID: 31777176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel Dose Escalation Approaches for Stereotactic Body Radiotherapy to Adrenal Oligometastases: A Single-Institution Experience.
    Figura NB; Oliver DE; Mohammadi H; Martinez K; Grass GD; Hoffe SE; Johnstone PAS; Frakes JM
    Am J Clin Oncol; 2020 Feb; 43(2):107-114. PubMed ID: 31764023
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stereotactic body radiotherapy (SBRT) for Stage I lung cancer.
    Nagata Y; Kimura T
    Jpn J Clin Oncol; 2018 May; 48(5):405-409. PubMed ID: 29635536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.